<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163051">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01810796</url>
  </required_header>
  <id_info>
    <org_study_id>HRanTrop</org_study_id>
    <nct_id>NCT01810796</nct_id>
  </id_info>
  <brief_title>Pathophysiology and Prevention of Perioperative Myocardial Injury: A Prospective Randomized Controlled Trial</brief_title>
  <official_title>Pathophysiology and Prevention of Perioperative Myocardial Injury: A Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <authority>Israel: Ethics Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Working hypothesis and aims: 1) To explore the pathophysiology of postoperative troponin
      elevations and 2) whether ranolazine, a new anti-ischemic drug that has no effect on blood
      pressure or heart rate, prevents postoperative myocardial injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High-risk patients undergoing non cardiac surgery will be randomized to receive either
      Ranolazine or placebo perioperatively and troponin will be measured on the first 3 days
      after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Postoperative troponin</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Coronary Artery Disease,</condition>
  <arm_group>
    <arm_group_label>Ranolazine treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranolazine 500-1000mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Ranolazine versus placebo</description>
    <arm_group_label>Ranolazine treatment</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - All patients age 18 and above, undergoing major surgery that require at least 24 hours
        (overnight) stay in the post anesthesia care unit (PACU) or intensive care unit (ICU), and
        who either have known history of CAD or at least 3 of the following Revised Cardiac Risk
        Index (RCRI) criteria29F17: 1) high-risk type of surgery, 2) history of ischemic heart
        disease, 3) history of congestive heart failure, 4) history of cerebrovascular disease, 5)
        diabetes mellitus, 6) renal failure (creatinine &gt; 2mg/ml).

        Exclusion Criteria:

          -  Pregnancy, LV ejection fraction â‰¤35%, patients with severe valvular disease, patients
             with poor echocardiographic images, patients who cannot swallow the pill after
             surgery, refusal to participate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giora Landesberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giora Landesberg, Assoc. Prof.</last_name>
    <phone>97226777269</phone>
    <email>gio@cc.huji.ac.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah - Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giora Landesberg, Assoc. Prof.</last_name>
      <phone>97226777269</phone>
      <email>gio@cc.huji.ac.il</email>
    </contact>
    <investigator>
      <last_name>Giora Landesberg, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 13, 2013</lastchanged_date>
  <firstreceived_date>March 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>Giora Landesberg</investigator_full_name>
    <investigator_title>Associate Profesor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
